The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma
Details
Publication Year 2021-04,Volume 21,Issue #4,Page 413-424
Journal Title
Expert Review of Anticancer Therapy
Publication Type
Review
Abstract
Introduction: With limited recent therapeutic changes, malignant pleural mesothelioma (MPM) is associated with poor survival and death within 12 months, making it one of the most lethal malignancies. Due to unregulated asbestos use in developing countries and home renovation exposures, cases of MPM are likely to present for decades. As MPM is largely driven by dysregulation of tumor suppressor genes, researchers have examined other mechanisms of subverting tumor proliferation and spread. Over-expression of pro-survival BCL-2 family proteins impairs cells from undergoing apoptosis, and BH3-mimetics targeting them are a novel treatment option across various cancers, though have not been widely investigated in MPM.Areas covered: This review provides an overview of MPM and its current treatment landscape. It summarizes the role of BCL-2 family proteins in tumorigenesis and the therapeutic potential of BH3-mimetics . Finally, it discusses the role of BCL-2 proteins in MPM and the pre-clinical rationale for investigating BH3-mimetics as a therapeutic strategy.Expert opinion: As a disease without readily actionable oncogene driver mutations and with modest benefit from immune checkpoint inhibition, novel therapeutic options are urgently needed for MPM. Hence, BH3-mimetics provide a promising treatment option, with evidence supporting dependence on pro-survival BCL-2 proteins for MPM cell survival.
Keywords
Antineoplastic Agents/*pharmacology; Apoptosis/drug effects; Biomimetic Materials/pharmacology; Cell Survival; Humans; Mesothelioma/*drug therapy/pathology; Molecular Targeted Therapy; Pleural Neoplasms/*drug therapy/pathology; Proto-Oncogene Proteins c-bcl-2/metabolism; Survival Rate; Apoptosis; BCL-2 family proteins; BH3-mimetics; cell death; malignant pleural mesothelioma
Department(s)
Medical Oncology
PubMed ID
33238762
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-05-23 08:13:53
Last Modified: 2025-05-23 08:15:07

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙